A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Incyte Corporation
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
City of Hope Medical Center
Universitätsklinikum Hamburg-Eppendorf
Therapeutic Advances in Childhood Leukemia Consortium
Alliance for Clinical Trials in Oncology
Therapeutic Advances in Childhood Leukemia Consortium
Eastern Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
BTG International Inc.
South Plains Oncology Consortium
Gruppo Italiano Malattie EMatologiche dell'Adulto
Takeda
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Children's Hospital of Philadelphia
Therapeutic Advances in Childhood Leukemia Consortium
Gruppo Italiano Malattie EMatologiche dell'Adulto
Wake Forest University Health Sciences
Nanfang Hospital, Southern Medical University
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Children's Oncology Group
Dana-Farber Cancer Institute
Massachusetts General Hospital
Fred Hutchinson Cancer Center
Vanderbilt University Medical Center
Dana-Farber Cancer Institute
Children's Oncology Group
Children's Oncology Group